Long-Term Self-Renewing Human Intestinal Organoids Derived From Biopsy Crypts: Crypt-Villus Axis Reconstitution, Enterocyte Differentiation, and Drug Transporter Expression Fidelity

This study investigates long-term culture conditions, crypt-villus axis reconstitution, and enterocyte drug transporter expression fidelity in human intestinal organoids derived from endoscopic biopsy crypts within the context of stem cell biology and gastrointestinal organoid technology, an area of growing scientific importance given its implications for intestinal drug absorption and metabolism modeling, patient-derived organoid pharmacology screening, and gastrointestinal disease modeling. Using optimization of Wnt3a, R-spondin-1, Noggin, and EGF concentrations for human intestinal organoid culture with transcriptomic, immunofluorescence, and drug transporter mRNA/protein quantification at passages 5, 20, and 50, we examine Wnt gradient reconstitution maintaining crypt-base columnar stem cell niche while Notch-Delta lateral inhibition drives enterocyte versus goblet cell fate specification, recapitulating in vivo crypt-villus axis polarity in 3D culture in organoids derived from 48 biopsy specimens (24 small intestine, 24 colon) from 12 donors, cultured through passage 50 with characterization at passages 5, 20, and 50 drawn from basement membrane extract (Matrigel) dome cultures in 24-well plates at 37 C with complete medium exchanges every 2 days and passaging every 5-7 days. Results indicate that optimized niche factor conditions maintain organoid viability and crypt-villus architecture to passage 50 (>12 months), with drug transporter expression (CYP3A4, P-gp) retaining 84.2% of primary tissue levels at passage 20 declining to 62.4% at passage 50 (p < 0.001), with 84.2% drug transporter retention at passage 20; 62.4% at passage 50 vs. primary tissue as the primary quantitative benchmark. Concordance between primary and confirmatory measurement approaches exceeded 93%, validating the analytical framework. These findings contribute empirically to stem cell biology and gastrointestinal organoid technology and carry actionable implications for the design of programs and policies targeting intestinal drug absorption and metabolism modeling, patient-derived organoid pharmacology screening, and gastrointestinal disease modeling.